Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness and Safety in the Use of Janus Kinase Inhibitors in Combination With Other Classic or Biological Systemic Treatments: Real-World Clinical Practice Experience.

Actas dermo-sifiliograficas·2025
Same author

Effectiveness and safety in the use of Janus kinase inhibitors in combination with other classic or biological systemic treatments: real-world clinical practice experience.

Actas dermo-sifiliograficas·2025
Same author

A New Paradigm in the Management of Scalp Pruritus: Findings From the SCALP-PR Trial.

Actas dermo-sifiliograficas·2024
Same author

[Translated article] Changes in the Location of Cutaneous Melanoma Over the Past 30 Years. A Retrospective Observational Study.

Actas dermo-sifiliograficas·2024
Same author

[Translated article] Survival Analysis and Prognostic Factors in a Case Series of 148 Cutaneous T-Cell Lymphomas.

Actas dermo-sifiliograficas·2024
Same author

A New Paradigm in the Management of Scalp Pruritus: Findings From the SCALP-PR Trial.

Actas dermo-sifiliograficas·2024
Same journal

Fingolimod-associated lymphomatoid papulosis.

Actas dermo-sifiliograficas·2026
Same journal

Demodicosis: update and treatment with laser and other light sources.

Actas dermo-sifiliograficas·2026
Same journal

New treatments for adult female acne.

Actas dermo-sifiliograficas·2026
Same journal

First regulations of the Spanish Society of Dermatology (1909).

Actas dermo-sifiliograficas·2026
Same journal

Long-hair FUE: advantages and disadvantages of the most recent technique in hair transplantation.

Actas dermo-sifiliograficas·2026
Same journal

Sunburns, Tanning, and Social Media: A Descriptive Study Among Spanish University Students.

Actas dermo-sifiliograficas·2026
See all related articles

Related Experiment Video

Updated: Jul 11, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

470

[Translated article] Sarcoid-like Reactions to Immune Checkpoint Inhibitors.

C Torrecilla-Vall-Llossera1, A Jucglà Serra1, J Molinero Caturla1

  • 1Servicio de Dermatología, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.

Actas Dermo-Sifiliograficas
|November 3, 2023
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors (ICIs) can cause sarcoid-like skin reactions. These reactions are typically mild, often don't require stopping ICI treatment, and are confirmed by histology.

Keywords:
GranulomasImmune checkpoint inhibitorsImmunotherapyInhibidores de puntos de control inmunitarioInmunoterapiaSarcoidosis

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K

Related Experiment Videos

Last Updated: Jul 11, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

470
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K

Area of Science:

  • Dermatology
  • Oncology
  • Immunology

Background:

  • Immune checkpoint inhibitors (ICIs) are crucial cancer therapies.
  • ICIs can trigger immune-mediated adverse events, including cutaneous reactions.
  • Sarcoid-like reactions are a recognized, albeit uncommon, adverse event of ICIs.

Purpose of the Study:

  • To analyze clinical and histologic features of sarcoid-like reactions induced by ICIs.
  • To evaluate the management and outcomes of these ICI-induced reactions.
  • To differentiate ICI-induced sarcoid-like reactions from tumor progression.

Main Methods:

  • Retrospective analysis of clinical and histologic data.
  • Study period: 2019-2022.
  • Inclusion criteria: Patients treated with ICIs who developed cutaneous sarcoid-like reactions.

Main Results:

  • Seven patients (6 female, 1 male, median age 65) were identified.
  • Median time to onset of reaction was 4 months.
  • Common presentations included papular sarcoidosis of the knees and subcutaneous sarcoidosis.
  • Histologic confirmation was achieved in all cases, showing no difference from idiopathic sarcoidosis.
  • Only two patients required ICI discontinuation.
  • Reactions were generally mild.

Conclusions:

  • ICI-induced sarcoid-like reactions are typically mild and manageable.
  • Histologic confirmation is vital to exclude tumor progression.
  • Discontinuation of ICI therapy is often unnecessary.